Compare Cipla with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 28.6 34.5 82.9% View Chart
P/BV x 4.0 4.7 85.6% View Chart
Dividend Yield % 0.5 0.6 90.0%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-20
DR. REDDYS LAB
Mar-20
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs5863,363 17.4%   
Low Rs3572,352 15.2%   
Sales per share (Unadj.) Rs207.01,054.2 19.6%  
Earnings per share (Unadj.) Rs18.6121.9 15.3%  
Cash flow per share (Unadj.) Rs33.2190.2 17.4%  
Dividends per share (Unadj.) Rs4.0025.00 16.0%  
Dividend yield (eoy) %0.80.9 97.0%  
Book value per share (Unadj.) Rs195.5938.7 20.8%  
Shares outstanding (eoy) m806.35166.17 485.3%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.32.7 84.0%   
Avg P/E ratio x25.323.4 108.1%  
P/CF ratio (eoy) x14.215.0 94.6%  
Price / Book Value ratio x2.43.0 79.2%  
Dividend payout %21.520.5 104.9%   
Avg Mkt Cap Rs m379,912474,831 80.0%   
No. of employees `00025.821.7 119.4%   
Total wages/salary Rs m30,27033,802 89.6%   
Avg. sales/employee Rs Th6,459.68,091.0 79.8%   
Avg. wages/employee Rs Th1,171.21,561.3 75.0%   
Avg. net profit/employee Rs Th580.2935.8 62.0%   
INCOME DATA
Net Sales Rs m166,949175,170 95.3%  
Other income Rs m3,4426,206 55.5%   
Total revenues Rs m170,391181,376 93.9%   
Gross profit Rs m32,06024,421 131.3%  
Depreciation Rs m11,74711,348 103.5%   
Interest Rs m1,974983 200.8%   
Profit before tax Rs m21,78218,296 119.1%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m0561 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,312-1,403 -449.9%   
Profit after tax Rs m14,99520,260 74.0%  
Gross profit margin %19.213.9 137.7%  
Effective tax rate %29.0-7.7 -377.9%   
Net profit margin %9.011.6 77.7%  
BALANCE SHEET DATA
Current assets Rs m117,038125,991 92.9%   
Current liabilities Rs m43,93172,141 60.9%   
Net working cap to sales %43.830.7 142.4%  
Current ratio x2.71.7 152.5%  
Inventory Days Days9673 131.0%  
Debtors Days Days85105 81.2%  
Net fixed assets Rs m107,42483,854 128.1%   
Share capital Rs m1,613831 194.0%   
"Free" reserves Rs m156,018155,157 100.6%   
Net worth Rs m157,630155,988 101.1%   
Long term debt Rs m23,6931,304 1,816.9%   
Total assets Rs m236,626232,253 101.9%  
Interest coverage x12.019.6 61.4%   
Debt to equity ratio x0.20 1,798.0%  
Sales to assets ratio x0.70.8 93.5%   
Return on assets %7.29.1 78.4%  
Return on equity %9.513.0 73.2%  
Return on capital %12.812.6 101.8%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03684,193 66.6%   
Fx outflow Rs m6,76439,616 17.1%   
Net fx Rs m49,27244,577 110.5%   
CASH FLOW
From Operations Rs m30,68529,841 102.8%  
From Investments Rs m1,040-4,923 -21.1%  
From Financial Activity Rs m-29,488-25,159 117.2%  
Net Cashflow Rs m2,340-266 -879.8%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 1,030 Points, Nifty Tops 14,980-Mark; HDFC Bank Among Top Gainers(Closing)

Indian share markets witnessed huge buying interest during the extended closing hours today and ended their day on a strong note.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 24, 2021 (Close)

TRACK CIPLA

CIPLA - ELDER PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS